- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC).Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitionsand various organic initiatives. In 2010 the Domestic formulations business was sold to Abott for $3.7 billionand Diagnostic Services was sold to Super Religare Laboratories (SRL)
CA Alchemy Investments, a shareholder in Piramal Pharma, has re-pledged 9.84 Cr (98,400,000) shares, representing 7.39% of the company. Deutsche Bank AG, acting as a security agent, now holds a pledge over a total of 23.87 Cr (238,663,700) Piramal Pharma shares, accounting for 17.93% of the equity. This re-pledge follows...
Piramal Pharma reported ₹8,869 Cr revenue, ₹1,135 Cr EBITDA, and a ₹325.94 Cr net loss amid market headwinds. The company invested ₹890 Cr and US$90M in advanced therapies, boosting growth prospects. Operational excellence drove 22.6% emissions cut & 41% renewable energy, with advancing digital transformation.
Piramal Pharma (PPL) has acquired an additional 40.67% stake in Yapan Bio Private Limited for approximately ₹76 crores, increasing its total ownership to 74.00%. Yapan, now a PPL subsidiary, specializes as a Contract Development and Manufacturing Organization (CDMO) for vaccines and biologics. This strategic acquisition integrates Yapan's advanced large molecule...